TARGET AUDIENCE
This activity has been designed to meet the educational needs of medical and radiation oncologists, urologists and other allied healthcare professionals involved in the treatment of prostate cancer (PC).

OVERVIEW OF ACTIVITY
Cancers of the genitourinary (GU) system affect hundreds of thousands of individuals within the United States each year and account for more than a quarter of all newly diagnosed human cancers. Although GU cancers are a diverse array of distinct diseases, tumors of the prostate are among the most prevalent and are therefore the topic of extensive ongoing clinical research. As such, the management of this disease is constantly evolving, necessitating rapid and consistent access to learning opportunities for clinicians who provide care for these patients.

Several consensus- and evidence-based treatment guidelines are available and aim to assist clinicians with making PC management decisions in this dynamic clinical and research environment. However, in situations where multiple acceptable therapeutic options exist, such guidelines may not be particularly helpful at the time of decision-making. By exploring the perspectives of leading investigators regarding a number of clinical scenarios and reviewing key data sets, this activity will assist medical and radiation oncologists, urologists and other allied healthcare professionals in the development of evidence-based strategies for the treatment of PC.

LEARNING OBJECTIVES

• Appraise recent data on diagnostic and therapeutic advances in PC, and integrate this information, as appropriate, into current clinical care.
• Evaluate emerging clinical trial data with available and investigational immunotherapeutic, chemotherapeutic and secondary hormonal agents in the management of nonmetastatic PC, and consider this information in the discussion of protocol and nonresearch treatment options.
• Explore available data with cytotoxic and secondary hormonal therapy in the setting of hormone-sensitive metastatic PC, and consider this information when designing treatment plans for appropriate individuals.
• Effectively apply evidence-based research findings in the determination of best-practice sequencing of available immunotherapeutic, chemotherapeutic and secondary hormonal agents for patients with metastatic castration-resistant PC.
• Consider available research data and expert perspectives on the efficacy and safety of radium-223 chloride as monotherapy or in combination with other treatment modalities for advanced PC, and use this information to appropriately integrate this radiopharmaceutical agent into clinical practice.
• Assess emerging data on the prevalence and landscape of mutations in DNA repair genes (eg, BRCA1, BRCA2, ATM) in metastatic PC and their potential therapeutic relevance.

ACCREDITATION STATEMENT
This activity has been planned and implemented in accordance with the accreditation requirements and policies of the Accreditation Council for Continuing Medical Education (ACCME) through the joint providership of Penn State College of Medicine and Research To Practice. Penn State College of Medicine is accredited by the ACCME to provide continuing medical education for physicians.

CREDIT DESIGNATION STATEMENT
CME credit is no longer available for this issue

HOW TO USE THIS CME ACTIVITY
This CME activity consists of a video component.
CME credit is no longer available for this issue

CONTENT VALIDATION AND DISCLOSURES
It is the policy of Research To Practice and Penn State College of Medicine to ensure balance, independence, objectivity and scientific rigor in all their educational programs. All faculty, planners and managers participating in this activity are required to disclose any relevant financial relationship(s) they (or spouse/partner) have with a commercial interest that benefits the individual in any financial amount that has occurred within the past 12 months; and the opportunity to affect the content of CME about the products or services of the commercial interest. Research To Practice and Penn State College of Medicine ensured that any conflicts of interest were resolved before the educational activity occurred.

FACULTY — The following faculty (and their spouses/partners) reported relevant conflicts of interest, which have been resolved through a conflict of interest resolution process:

Robert Dreicer, MD, MS
Section Head, Medical Oncology
Deputy Director, University of Virginia Cancer Center
Associate Director for Clinical Research
Co-Director, Paul Mellon Urologic Cancer Institute
Professor of Medicine and Urology
University of Virginia School of Medicine
Charlottesville, Virginia

Consulting Agreements: Astellas Pharma Global Development Inc, AstraZeneca Pharmaceuticals LP, Bristol-Myers Squibb Company, EMD Serono Inc, Genentech BioOncology, Orion, Sanofi Genzyme.

Karim Fizazi, MD, PhD
Head of the Department of Cancer Medicine
Institute Gustave Roussy
Professor in Oncology
University of Paris
Villejuif, France

Advisory Committee: Amgen Inc, Astellas Pharma Global Development Inc, Bayer HealthCare Pharmaceuticals, Janssen Biotech Inc, Merck, Sanofi Genzyme.

Daniel P Petrylak, MD
Professor of Medicine
Director, Prostate and GU Medical Oncology
Co-Director, Signal Transduction Program
Yale Cancer Center
New Haven, Connecticut

Consulting Agreements: Bayer HealthCare Pharmaceuticals, Bellicum Pharmaceuticals Inc, Dendreon Pharmaceuticals Inc, Exelixis Inc, Ferring Pharmaceuticals, Johnson & Johnson Pharmaceuticals, Medivation Inc, a Pfizer Company, Pfizer Inc, Roche Laboratories Inc, Sanofi Genzyme, Takeda Oncology, Tyme Technologies Inc; Contracted Research: Agensys Inc, AstraZeneca Pharmaceuticals LP, Bayer HealthCare Pharmaceuticals, Dendreon Pharmaceuticals Inc, Endocyte Inc, Genentech BioOncology, Innocrin Pharmaceuticals Inc, Johnson & Johnson Pharmaceuticals, Lilly, MedImmune Inc, Medivation Inc, a Pfizer Company, Merck, Novartis, OncoGenex Pharmaceuticals Inc, Pfizer Inc, Progenics Pharmaceuticals Inc, Roche Laboratories Inc, Sanofi Genzyme, SOTIO LLC, Takeda Oncology; Ownership Interest: Bellicum Pharmaceuticals Inc, Tyme Technologies Inc.

A Oliver Sartor, MD
CE and Bernadine Laborde Professor for Cancer Research
Medical Director, Tulane Cancer Center
Assistant Dean for Oncology
Tulane Medical School
New Orleans, Louisiana

Consulting Agreements: Advanced Accelerator Applications, AstraZeneca Pharmaceuticals LP, Bayer HealthCare Pharmaceuticals, Bellicum Pharmaceuticals Inc, Bristol-Myers Squibb Company, Celgene Corporation, Constellation Pharmaceuticals, Dendreon Pharmaceuticals Inc, EMD Serono Inc, Endocyte Inc, Johnson & Johnson Pharmaceuticals, OncoGenex Pharmaceuticals Inc, Pfizer Inc, Sanofi Genzyme; Contracted Research: Bayer HealthCare Pharmaceuticals, Endocyte Inc, Innocrin Pharmaceuticals Inc, Johnson & Johnson Pharmaceuticals, Sanofi Genzyme.

Mary-Ellen Taplin, MD
Chair, Executive Committee for Clinical Research
Director of Clinical Research
Lank Center for Genitourinary Oncology
Institute Physician
Professor of Medicine, Harvard Medical School
Dana-Farber Cancer Institute
Boston, Massachusetts

Advisory Committee: Clovis Oncology, Janssen Biotech Inc, Sanofi Genzyme; Consulting Agreement: Constellation Pharmaceuticals; Contracted Research: Bayer HealthCare Pharmaceuticals, Janssen Biotech Inc, Pfizer Inc.

MODERATOR — Dr Love is president and CEO of Research To Practice, which receives funds in the form of educational grants to develop CME activities from the following commercial interests: AbbVie Inc, Acerta Pharma, Adaptive Biotechnologies, Agendia Inc, Agios Pharmaceuticals Inc, Amgen Inc, Ariad Pharmaceuticals Inc, Array BioPharma Inc, Astellas Pharma Global Development Inc, AstraZeneca Pharmaceuticals LP, Baxalta Inc, Bayer HealthCare Pharmaceuticals, Biodesix Inc, bioTheranostics Inc, Boehringer Ingelheim Pharmaceuticals Inc, Boston Biomedical Pharma Inc, Bristol-Myers Squibb Company, Celgene Corporation, Clovis Oncology, CTI BioPharma Corp, Dendreon Pharmaceuticals Inc, Eisai Inc, Exelixis Inc, Foundation Medicine, Genentech BioOncology, Genomic Health Inc, Gilead Sciences Inc, Halozyme Inc, ImmunoGen Inc, Incyte Corporation, Infinity Pharmaceuticals Inc, Ipsen Biopharmaceuticals Inc, Janssen Biotech Inc, administered by Janssen Scientific Affairs LLC, Jazz Pharmaceuticals Inc, Kite Pharma Inc, Lexicon Pharmaceuticals Inc, Lilly, Medivation Inc, a Pfizer Company, Merck, Merrimack Pharmaceuticals Inc, Myriad Genetic Laboratories Inc, NanoString Technologies, Natera Inc, Novartis, Novocure, Onyx Pharmaceuticals, an Amgen subsidiary, Pfizer Inc, Pharmacyclics LLC, an AbbVie Company, Prometheus Laboratories Inc, Puma Biotechnology Inc, Regeneron Pharmaceuticals Inc, Sanofi Genzyme, Seattle Genetics, Sigma-Tau Pharmaceuticals Inc, Sirtex Medical Ltd, Spectrum Pharmaceuticals Inc, Taiho Oncology Inc, Takeda Oncology, Tesaro Inc, Teva Oncology and Tokai Pharmaceuticals Inc.

PENN STATE COLLEGE OF MEDICINE — Faculty and staff involved in the development and review of this activity have disclosed no relevant financial relationships.

RESEARCH TO PRACTICE STAFF AND EXTERNAL REVIEWERS — The scientific staff and reviewers for Research To Practice have no relevant conflicts of interest to disclose.

This educational activity may contain discussion of published and/or investigational uses of agents that are not indicated by the Food and Drug Administration. Research To Practice and Penn State College of Medicine do not recommend the use of any agent outside of the labeled indications. Please refer to the official prescribing information for each product for discussion of approved indications, contraindications and warnings. The opinions expressed are those of the presenters and are not to be construed as those of the provider or grantors.

This activity is supported by educational grants from AstraZeneca Pharmaceuticals LP, Bayer HealthCare Pharmaceuticals, Janssen Biotech Inc, administered by Janssen Scientific Affairs LLC, and Sanofi Genzyme.

Hardware/Software Requirements:
A high-speed Internet connection
A monitor set to 1280 x 1024 pixels or more
Internet Explorer 11 or later, Firefox 56 or later, Chrome 61 or later, Safari 11 or later, Opera 48 or later
Adobe Flash Player 27 plug-in or later
Adobe Acrobat Reader
(Optional) Sound card and speakers for audio

Release date: March 2018
Expiration date: March 2019